Effects of Risedronate on Osteoarthritis of the Knee
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind,randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cartilage loss preserved the structural integrity of subchondral bone by risedronate treatment (15 mg/day and 50 mg/week). Another subanalysis study (n = 1,885)revealed that C-terminal crosslinking telopeptide of type II collagen (CTX-II) decreased with risedronate treatment in a dose-dependent manner, and levels reached after 6 months were associated with radiological progression at 2 years. The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone. The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.
Abstract
The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind,randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cartilage loss preserved the structural integrity of subchondral bone by risedronate treatment (15 mg/day and 50 mg/week). Another subanalysis study (n = 1,885)revealed that C-terminal crosslinking telopeptide of type II collagen (CTX-II) decreased with risedronate treatment in a dose-dependent manner, and levels reached after 6 months were associated with radiological progression at 2 years. The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone. The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.
참고문헌 (28)
- Sowers M, "Epidemiology of risk factors for osteoarthritis:systemic factors", Curr Opin Rheumatol, 13, pp.447~451 (2001)
- Kawaguchi H, "Regulation of osteoarthritis development by Wntbeta-catenin signaling through the endochondral ossification process", J Bone Miner Res, 24, pp.8~11 (2009)
- Zhang W, "OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines", Osteoarthritis Cartilage, 16, pp.137~162 (2008)
- Spector TD, "Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis", Aging Clin Exp Res, 15, pp.413~418 (2003)
- Hayami T, "The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model", Arthritis Rheum, 50, pp.1193~1206 (2004)
- Muehleman C, "The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage", Osteoarthritis Cartilage, 10, pp.226~233 (2002)
- Bendele AM, "Spontaneous cartilage degeneration in guinea pigs", Arthritis Rheum, 31, pp.561~565 (1988)
- "Arthritis Res Ther", 2005, R625~633
- Bingham CO 3rd, "Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study", Arthritis Rheum, 54, pp.3494~3507 (2006)
- Buckland-Wright JC, "A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients", Rheumatology (Oxford), 46, pp.257~264 (2007)
- Garnero P, "Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial", Osteoarthritis Cartilage, 16, pp.660~666 (2008)
- Bruyère O, "Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system", BMC Musculoskelet Disord, 9, pp.165~ (2008)
- Altman R, "Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association", Arthritis Rheum, 29, pp.1039~1049 (1986)
- Bellamy N, "Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee", J Rheumatol, 15, pp.1833~1840 (1988)
- Bettica P, "Evidence for increased bone resorption in patients with progressive knee osteoarthritis:longitudinal results from the Chingford study", Arthritis Rheum, 46, pp.3178~3184 (2002)
- Li B, "Mechanical and material properties of the subchondral bone plate from the femoral head of patients with osteoarthritis or osteoporosis", Ann Rheum Dis, 56, pp.247~254 (1997)
- Buckland-Wright JC, "Quantitative microfocal radiographic assessment of osteoarthritis of the knee from weight bearing tunnel and semiflexed standing views", J Rheumatol, 21, pp.1734~1741 (1994)
- Wluka AE, "Tibial plateau size is related to grade of joint space narrowing and osteophytes in healthy women and in women with osteoarthritis", Ann Rheum Dis, 64, pp.1033~1037 (2005)
- Jones G, "Early radiographic osteoarthritis is associated with substantial changes in cartilage volume and tibial bone surface area in both males and females", Osteoarthritis Cartilage, 12, pp.169~174 (2004)
- Tissakht M, "Calculated stress-shielding in the distal femur after total knee replacement corresponds to the reported location of bone loss", J Orthop Res, 14, pp.778~785 (1996)
- Bettica P, "Evidence for increased bone resorption in patients with progressive knee osteoarthritis:longitudinal results from the Chingford study", Arthritis Rheum, 46, pp.3178~3184 (2002)
- Dufresne TE, "Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography", Calcif Tissue Int, 73, pp.423~432 (2003)
- Oestergaard S, "Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation", Arthritis Rheum, 54, pp.2441~2451 (2006)
- Bay-Jensen AC, "Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage", Osteoarthritis Cartilage, 16, pp.615~623 (2008)
- Saag KG, "Bisphosphonates for osteoarthritis prevention: “Holy Grail” or not?", Ann Rheum Dis, 67, pp.1358~1359 (2008)
- Neogi T, "The effect of alendronate on progression of spinal osteophytes and discspace narrowing", Ann Rheum Dis, 67, pp.1427~1430 (2008)
- Bruyere O, "Effects of strontium ranelate on spinal osteoarthritis progression", Ann Rheum Dis, 67, pp.335~339 (2008)